Roche– tag –
-
Roche Diagnostics Bolsters Comprehensive Point-of-Care Testing Portfolio for Diverse Clinical Settings
Roche Diagnostics USA Overview Roche Diagnostics is expanding its robust portfolio of point-of-care (POC) diagnostic solutions, encompassing devices, platforms, digital products, and services. These integrated solutions aim to deliver ra... -
Roche’s Elecsys® pTau217 Blood Test Gains FDA Clearance, Enabling Alzheimer’s Amyloid Pathology Identification in Primary Care for Individuals Aged 55+
Roche (Press Release) USA Overview Roche has announced FDA clearance for its Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test, offering a single, blood-based option for clinicians in both primary and specialty care to identify Alz... -
Roche’s PATHWAY® HER2 and VENTANA® HER2 Dual ISH Companion Diagnostics Approved by FDA for ZIIHERA® Eligibility in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
BioSpace USA Overview Roche has received FDA approval for two companion diagnostic tests, PATHWAY® HER2 (4B5) and VENTANA® HER2 Dual ISH DNA Probe Cocktail, to identify patients with HER2-positive metastatic gastroesophageal adenocarcino... -
Roche Secures EU CE Mark for Elecsys pTau217 Alzheimer’s and Elecsys IGRA TB Blood Tests
GlobeNewswire Switzerland Overview Roche announced that its Elecsys pTau217 blood test for Alzheimer's disease diagnosis and Elecsys IGRA TB test for latent tuberculosis infection have received EU CE mark certification. This approval, pa... -
Roche Unveils AXELIOS 1 Next-Gen Sequencing Platform and cobas® Mass Spec at ADLM 2026, Addressing Lab Workforce & Workflow Challenges
PR Newswire (via Roche) Switzerland Overview Roche showcased advanced integrated diagnostic solutions at ADLM 2026, featuring the new AXELIOS 1 next-generation sequencing platform and cobas® Mass Spec solution. These innovations aim to e... -
Roche Reports 6% H1 2026 Sales Growth, Secures CE Marks for New Alzheimer’s and TB Blood Tests, Acquires AI Pathology Firm PathAI
Roche (Official Press Release), Fierce Biotech Switzerland Overview Roche reported robust 6% sales growth in H1 2026 at constant exchange rates, with diagnostics contributing 3% despite healthcare price reforms in China. Key advancements... -
Roche Maximizes Clinical Value by Accelerating Emergency and Infectious Disease Diagnostics with POCT Technology
Roche Switzerland Overview Roche emphasizes that Point-of-Care Testing (POCT) maximizes its value in urgent care and infectious disease diagnostics, such as sepsis and COVID-19, by enabling rapid clinical decision-making. Advances in bio... -
Roche Diagnostics Expands Focus on Diabetes Care, Awaiting US Approval for Accu-Chek Smartguide CGM
Indianapolis Business Journal USA Overview Swiss pharmaceutical giant Roche is continuing its expansion project within its diagnostics division in Indianapolis, with an intensified focus on diabetes care. The company is particularly awai... -
Roche Diagnostics Strengthens Comprehensive POCT Portfolio, Driving Rapid and Accurate On-Site Diagnostics for Critical Conditions
Roche Diagnostics Switzerland Overview Roche Diagnostics, in an update dated June 23, 2026, announced the strengthening of its comprehensive Point of Care (POCT) solutions portfolio. The company emphasizes the critical role of POCT in fr...
1